Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 375.00, up by 0.40 points or 0.11% from its previous closing of Rs. 374.60 on the BSE.

The scrip opened at Rs. 375.00 and has touched a high and low of Rs. 376.25 and Rs. 369.65 respectively. So far 57923 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 484.10 on 01-Apr-2019 and a 52 week low of Rs. 350.40 on 13-May-2019.

Last one week high and low of the scrip stood at Rs. 414.50 and Rs. 369.65 respectively. The current market cap of the company is Rs. 90011.05 crore.

The promoters holding in the company stood at 54.56%, while Institutions and Non-Institutions held 32.96% and 12.48% respectively.

Sun Pharmaceutical Industries’ wholly owned subsidiary has launched Riomet ER in the U.S. as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type 2 diabetes mellitus. Riomet ER was approved by the U.S. Food and Drug Administration (USFDA) on August 29, 2019.

Riomet ER, dosed once daily, is the first and only FDA-approved liquid formulation of extended-release metformin. It can be prepped and poured, thereby eliminating the need to crush medication. The availability of a liquid formulation addresses the needs of patients with type 2 diabetes mellitus, including residents in long-term care facilities, who often have issues swallowing solid medications. Riomet ER offers dosing flexibility and an acceptable taste.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.